معرفی
Professor Anthony Chalmers serves as Chair of Clinical Oncology at the Institute of Cancer Sciences, University of Glasgow, based at the Wolfson Wohl Cancer Research Centre, Garscube Estate. His research focuses on improving outcomes for patients with glioblastoma, the most aggressive primary brain tumor, through innovative approaches to overcome treatment resistance.
Dr. Chalmers' research interests center on DNA repair mechanisms, particularly the poly(ADP-ribose) polymerase (PARP) pathway, and how inhibiting these proteins can enhance the effectiveness of radiotherapy and chemotherapy for glioblastoma. His laboratory is developing clinical trials testing PARP inhibitors in combination with standard treatments and investigating how the tumor microenvironment influences radiation responses. His research group has pioneered novel 3D cell culture systems that better model the glioblastoma microenvironment for therapeutic testing.
Analysis of his recent publications reveals a strong focus on clinical translation of basic radiation biology discoveries, with particular emphasis on glioblastoma treatment optimization, radiation dosimetry, and novel radiosensitizing approaches. His work spans from fundamental molecular mechanisms to large-scale clinical implementation.
Dr. Chalmers has contributed to numerous collaborative research efforts in radiation oncology, with recent work examining healthcare disparities in neuro-oncology services, the impact of the pandemic on radiotherapy delivery, and quality-of-life considerations in elderly brain tumor patients.
His leadership extends to professional development initiatives, as evidenced by his work creating guides for early-career professionals in neuro-oncology conferences. His research continues to bridge the gap between laboratory discoveries and clinical implementation in radiation oncology.
